Navigation Links
Osteoporosis Drugs' Safety Subject of FDA Panel
Date:9/9/2011

solute risk of developing osteonecrosis of the jaw is between 1 in 10,000 and 1 in 400,000 among people taking these drugs for osteoporosis.

But when high-dose bisphosphonates are used to slow the spread of bone cancer, the risk rises, affecting anywhere from 1 percent to 15 percent of patients, she said.

For atypical femur (thigh) fractures, the absolute risk linked to bisphosphonates is about 1 to 5 fractures in 10,000 bisphosphonate users, she said.

Besides hip fractures, bisphosphonates prevent spine, wrist and arm fractures, Shane said.

The FDA wants the committee to consider whether current data support long-term use of bisphosphonates for treating or preventing osteoporosis. The experts also are to consider whether a time limit should be placed on their use, and if patients who need long-term therapy would benefit from a "drug holiday," meaning time off the medication.

"I am really not in favor of putting a limit on use of bisphosphonates and dictating the use of drug holidays," Shane said. "We have very little evidence to support the use of drug holidays or no drug holidays."

If the committee finds that bisphosphonates do pose a serious risk, it may suggest revising the drugs' labels to reflect these potential dangers. The labels already carry a warning about atypical femur fractures.

Dr. Nelson Watts, director of the University of Cincinnati Bone Health and Osteoporosis Center and co-author of a 2010 study on long-term use of bisphosphonates, said length of treatment should be considered on an individual basis. His study suggested patients at mild risk might discontinue drug treatment after five years for as long as no fractures occurred and no bone loss was evident. Higher-risk patients could take the drugs for 10 years and perhaps then take a "holiday" from bisphosphonates of one or two years.

"It would probably be helpful if FDA or some official organization could provide guidelines on duration of tre
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. New study highlights what works in osteoporosis treatment
2. Program announced for 1st Middle-East & Africa Osteoporosis Meeting
3. Preliminary program announced for 2nd Asia-Pacific Osteoporosis & Bone Meeting
4. Gene combinations are found to be related to hip osteoporosis in postmenopausal women
5. Study links long-term use of osteoporosis drugs to unusual fractures
6. An extra 5 years of life an unexpected benefit of osteoporosis treatment
7. Researchers discover age of onset of puberty predicts adult osteoporosis risk
8. Loyola physician helps develop national guidelines for osteoporosis
9. New Osteoporosis Screening Recommendations Issued
10. Belly fat puts women at risk for osteoporosis
11. Taking a break from osteoporosis drugs can protect bones
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Osteoporosis Drugs' Safety Subject of FDA Panel 
(Date:9/1/2014)... (PRWEB) September 02, 2014 “Australia Hernia ... on the Australia Hernia Repair market. The report provides ... and average prices (in US dollars) within market segments ... and Synthetic 3D Meshes) ,     Composite Meshes and ... a surgical operation for the correction of a hernia ...
(Date:9/1/2014)... Sept. 1, 2014 (HealthDay News) -- Having regular family ... health effects of "cyberbullying," a new study suggests. ... thoughts, according to experts. "One in five adolescents ... for Health and Social Policy at McGill University in ... adolescents use social media, and online harassment and abuse ...
(Date:9/1/2014)... health and substance use problems in adolescents but ... consequences of cyberbullying and also be beneficial for ... Ph.D., of McGill University, Montreal, Canada, and colleagues. ... experienced recent online bullying and cyberbullying, like traditional ... problems in teens as well as the misuse ...
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. 30, ... experimental drug was more effective than standard treatment at ... According to the study authors, the trial was stopped ... drug, dubbed LCZ696. In the trial, 26.5 ... either died or were hospitalized due to heart failure, ...
(Date:9/1/2014)... News) -- Watching action shows on TV may be bad ... much more snack food while watching action films and programs ... "We find that if you,re watching an action movie ... author Aner Tal, of the Cornell Food and Brand Lab, ... more distracting the program is, the more you will eat." ...
Breaking Medicine News(10 mins):Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 2Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 3Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 4Health News:Family Meals May Defuse Cyberbullying's Impact, Study Says 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 3Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2
... halt premature labor may be associated with brain damage and intestinal ... on the issue published today in American Journal of Obstetrics and ... are faced with the possibility of delivering a baby who is ... will be given both a tocolytic agent, or drug used to ...
... (positron emission tomography) that measures uptake of sugar in ... type of dementia often mistaken for Alzheimers disease, a ... has found. , The scan, FDG-PET, helped six doctors ... dementia (FTD) and Alzheimers in almost 90 percent of ...
... year of advancing cancer research, the American Association for ... Europe, and Asia. The AACR has teamed with ... Science, Technology and Research (A*STAR) to hold the first ... Singapore: the AACR Centennial Conference on Translational Cancer Medicine: ...
... 1, 2007) Diabetes is a very common illness that ... it is estimated an additional 54 million Americans have pre-diabetes, ... are higher than normal but not high enough for a ... determine whether glucose and insulin levels are associated with a ...
... ADA President Mark J. Feldman:, "The American Dental ... for introducing legislation that will help bring more,dentists into ... too many people lack sufficient access to the basic ... Native American Full Access to Dental Care Act (H.R. ...
... Wash., Nov. 1 BLU-MED Response Systems ... and distribution,facility near Boise, Idaho. BLU-MED produces ... use as mobile field hospitals,emergency medical stations, ... facilities are used by Federal, state and ...
Cached Medicine News:Health News:Common drug for stopping preterm labor may be harmful for babies 2Health News:PET scan distinguishes Alzheimer's from other dementia 2Health News:PET scan distinguishes Alzheimer's from other dementia 3Health News:Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference 2Health News:Increased glucose level is a strong risk factor for colorectal cancer 2Health News:Increased glucose level is a strong risk factor for colorectal cancer 3Health News:Statement by ADA President Mark J. Feldman on the Native American Full Access to Dental Care Act 2Health News:BLU-MED Response Systems Announces New Production Facility in Idaho 2
(Date:9/1/2014)... 2014 Reportbuyer.com has added a new ... Lasers and Energy Devices Market Outlook to 2020, ... Brazil Aesthetic Lasers and Energy Devices Market ... GlobalData,s new report, "Brazil Aesthetic Lasers and ... market data on the Brazil Aesthetic Lasers and ...
(Date:9/1/2014)... NEW YORK , Sept. 1, 2014 /PRNewswire/ ... new market research report is available in its ... Edition), 2014 - 2024 ... conjugates (ADCs) are a new class of therapeutic ... small pharmaceutical companies. Generally addressed as the marriage ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue:  Drug Discovery Technologies - A Global ... The development of new drugs ... extensive expenditure, in addition to consuming a lot ... new drug involves the utilizing high-throughput screening of ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPharma (TASE:CFBI), a ... Exchange, proceeds with the development of its,third drug ... is currently,in clinical trials and CF102, which is ... the EUALR annual congress of,rheumatology in-vitro and in ...
... of SLE,disease at 52 Weeks and demonstrated ... ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- ... of Phase 2,trial data demonstrating that LymphoStat-B(R) ... was well tolerated and improved quality of ...
Cached Medicine Technology:Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8